Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 13/20 | 0.51 |
| ▸ | PFKFB2 | O60825 | 1/20 | 0.47 |
| ▸ | PFKFB1 | P16118 | 1/20 | 0.47 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.47 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.46 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.46 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.45 |
| ▸ | KIT | P10721 | 1/20 | 0.45 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.44 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.44 |
| ▸ | TPX2 | Q9ULW0 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3349635 | 0.90 | ALK (0.61) | ALKPFKFB2PFKFB1PFKFB3MAPK8 | |
| SCHEMBL3353401 | 0.90 | ALK (0.60) | ALKMAPK8MAPK9MAPK10TNIK | |
| SCHEMBL3347388 | 0.88 | MAPK8 (0.50) | ALKPFKFB2PFKFB1PFKFB3MAPK8 | |
| SCHEMBL3350070 | 0.88 | ALK (0.51) | ALKMAPK8MAPK9MAPK10KIT | |
| SCHEMBL3348389 | 0.84 | ALK (0.53) | ALKMAPK8MAPK9MAPK10KIT | |
| SCHEMBL13539154 | 0.82 | ALK (0.53) | ALKMAPK8MAPK9MAPK10AURKA | |
| SCHEMBL3347888 | 0.81 | ALK (0.54) | ALKMAPK8MAPK9MAPK10AURKA | |
| SCHEMBL3351161 | 0.81 | ALK (0.52) | ALKMAPK8MAPK9MAPK10AURKA | |
| SCHEMBL3354806 | 0.79 | ALK (0.53) | ALKMAPK8MAPK9MAPK10AURKA | |
| SCHEMBL3348103 | 0.78 | ALK (0.52) | ALKMAPK8MAPK9MAPK10AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1749829-B1 | JNK inhibitors | EISAI R&D MAN CO LTD (JP) | 2010-11-03 | — | — | EP | disclosed |
| EP-1749829-B1 | JNK inhibitors | EISAI R&D MAN CO LTD (JP) | 2010-11-03 | — | — | EP | disclosed |
| US-20100035878-A1 | INHIBITORS OF C-JUN N-TERMINAL KINASES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS RELATING TO APOPTOSIS AND/OR INFLAMMATION | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2010-02-11 | — | — | US | disclosed |
| US-20100035878-A1 | INHIBITORS OF C-JUN N-TERMINAL KINASES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS RELATING TO APOPTOSIS AND/OR INFLAMMATION | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2010-02-11 | — | — | US | disclosed |
| US-20100035878-A1 | INHIBITORS OF C-JUN N-TERMINAL KINASES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS RELATING TO APOPTOSIS AND/OR INFLAMMATION | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2010-02-11 | — | — | US | disclosed |
| US-7645769-B2 | Inhibitors of c-Jun N-terminal kinases for the treatment of neurodegenerative disorders relating to apoptosis and/or inflammation | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2010-01-12 | — | — | US | disclosed |
| US-7645769-B2 | Inhibitors of c-Jun N-terminal kinases for the treatment of neurodegenerative disorders relating to apoptosis and/or inflammation | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2010-01-12 | — | — | US | disclosed |
| US-7645769-B2 | Inhibitors of c-Jun N-terminal kinases for the treatment of neurodegenerative disorders relating to apoptosis and/or inflammation | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2010-01-12 | — | — | US | disclosed |
| US-20070072896-A1 | Inhibitors of c-Jun N-terminal kinases for the treatment of neurodegenerative disorders relating to apoptosis and/or inflammation | EISAI CO., LTD. (JP) | 2007-03-29 | — | — | US | disclosed |
| US-20070072896-A1 | Inhibitors of c-Jun N-terminal kinases for the treatment of neurodegenerative disorders relating to apoptosis and/or inflammation | EISAI CO., LTD. (JP) | 2007-03-29 | — | — | US | disclosed |
| US-20070072896-A1 | Inhibitors of c-Jun N-terminal kinases for the treatment of neurodegenerative disorders relating to apoptosis and/or inflammation | EISAI CO., LTD. (JP) | 2007-03-29 | — | — | US | disclosed |
| EP-1749829-A1 | JNK inhibitors | Eisai London Research Laboratories Limited (GB) | 2007-02-07 | — | — | EP | disclosed |
| EP-1749829-A1 | JNK inhibitors | Eisai London Research Laboratories Limited (GB) | 2007-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035878-A1 | INHIBITORS OF C-JUN N-TERMINAL KINASES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS RELATING TO APOPTOSIS AND/OR INFLAMMATION | NFKBIA, CHUK, MAP3K1 | ALK 3869/4885PFKFB2 2959/4885PFKFB1 2656/4885 |
| US-20070072896-A1 | Inhibitors of c-Jun N-terminal kinases for the treatment of neurodegenerative disorders relating to apoptosis and/or inflammation | NFKBIA, CHUK, MAP3K1 | ALK 3869/4885PFKFB2 2959/4885PFKFB1 2656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.